#uniQure's #genetherapy for #Huntington's continued to slow disease progression over four years of follow-up in a clinical trial, but signs that #efficacy may be starting to wane spooked #investors.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#uniQure's #genetherapy for #Huntington's continued to slow disease progression over four years of follow-up in a clinical trial, but signs that #efficacy may be starting to wane spooked #investors.
@newsen.bsky.socialInvestigation Alert: uniQure Faces Scrutiny Following Recent Stock Plunge #United_States #New_York #uniQure #AMT-130 #NASDAQ_QURE
@hdfcures.bsky.socialuniQure issued a press release today announcing additional data from the ongoing Phase I/II clinical studies of AMT-130, their investigational gene therapy for Huntington's disease.
Read more: bit.ly/HDF-PR
#uniqure #scientificresearch #researchupdatehd #hdresearch #curehd
